title: Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy.
abstract: The purpose of this study was to assess metformin effects on high-density lipoprotein (HDL) composition of patients with HIV-associated lipodystrophy (LDHIV). Twenty-four adult outpatients were enrolled to receive metformin (1700 mg/d) during 6 months, but 2 were lost to follow-up and 6 stopped the drug due to adverse events (gastrointestinal in 5, and excessive weight loss in 1). From the 16 subjects who completed the study, 69% were female. At baseline, 3 and 6 months, we assessed: weight, waist and hip circumferences, blood pressure, fasting glucose and insulin, homeostasis model assessment of insulin resistance (HOMA2-IR), lipids, and HDL subfractions by microultracentrifugation. At 0 and 6 months, body fat distribution was assessed by computed tomography (CT) scan (L4 and middle femur). Metformin use was associated with reduction of mean weight (-2.4Kg at 6 months; p < 0.001), body mass index, waist, waist-to-hip ratio and a marked decrease in blood pressure (p < 0.001). Subcutaneous (p = 0.01) and total abdominal fat (p = 0.002) were reduced, but no change was found in visceral or thigh fat. No difference was detected on plasma glucose, insulin, HOMA2-IR, cholesterol or triglycerides, except for an increase in HDL3-cholesterol (from 21 mg/dL to 24 mg/dL, p = 0.002) and a reduction of nascent HDL (the fraction of plasma HDL-cholesterol not associated to subfractions HDL2 or HDL3) (p = 0.008). Adverse effects were very common, but most were gastrointestinal and mild. Thus, metformin use in LDHIV increases HDL3-cholesterol (probably due to improved maturation of HDL) and decreases blood pressure, weight, waist, and subcutaneous truncal fat, making this an attractive option for preventing cardiovascular disease in this population.
authors.affiliation: State University of Londrina (UEL), Londrina, PR, Brazil. leandro@portalendocrino.com.br
authors.forename: Leandro A
authors.initials: LA
authors.lastname: Diehl
authors.forename: Bruno A
authors.initials: BA
authors.lastname: Fabris
authors.forename: Décio S
authors.initials: DS
authors.lastname: Barbosa
authors.forename: Eliana C
authors.initials: EC
authors.lastname: De Faria
authors.forename: Susana L
authors.initials: SL
authors.lastname: Wiechmann
authors.forename: Alexandre J F
authors.initials: AJ
authors.lastname: Carrilho
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D050218:Body Fat Distribution; D008076:Cholesterol, HDL / Q000097:blood*; D005260:Female; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D008076:Cholesterol, HDL; D007004:Hypoglycemic Agents; D008687:Metformin